A New Diabetes Drug Class
Jun 16, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Jacob Roberts, PharmD Candidate 2021 of University of Colorado Denver Skaggs School of Pharmacy and Pharmaceutical Sciences
Imeglimin, a new, first-in-class blood-glucose-lowering agent, proves to be safe and efficient as monotherapy and adjunctive therapy to lower A1C in patients with type 2 diabetes.
A systematic review and meta-analysis published in the British Journal of Diabetes presented promising data for Imeglimin, a medication to treat diabetes using a novel mechanism of action. This drug is currently in phase 3 trials of human studies and is likely to continue in the approval process based on currently available data.
Imeglimin is a new medication in a class of glucose-lowering agents called "glimins." Studies in animal models show that its likely mechanism of action is "via a mitochondrial mechanism to increase glucose uptake by skeletal muscle, decrease hepatic glucose output, and increase glucose-dependent insulin secretion." It may also protect endothelial cells from damage caused by glucotoxicity and have beneficial cardiovascular effects....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.